{"name":"Taizhou Hanzhong biomedical co. LTD","slug":"taizhou-hanzhong-biomedical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HX008","genericName":"HX008","slug":"hx008","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HX008 + TACE","genericName":"HX008 + TACE","slug":"hx008-tace","indication":"Hepatocellular carcinoma (HCC) in combination with transarterial chemoembolization","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Temozolomide + TACE","genericName":"Temozolomide + TACE","slug":"temozolomide-tace","indication":"Glioblastoma","status":"phase_3"}]}],"pipeline":[{"name":"HX008","genericName":"HX008","slug":"hx008","phase":"phase_3","mechanism":"HX008 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"HX008 + TACE","genericName":"HX008 + TACE","slug":"hx008-tace","phase":"phase_3","mechanism":"HX008 is a PD-1 inhibitor combined with TACE (transarterial chemoembolization) to enhance anti-tumor immunity while delivering localized chemotherapy to hepatic tumors.","indications":["Hepatocellular carcinoma (HCC) in combination with transarterial chemoembolization"],"catalyst":""},{"name":"Temozolomide + TACE","genericName":"Temozolomide + TACE","slug":"temozolomide-tace","phase":"phase_3","mechanism":"Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells, while TACE is a minimally invasive procedure that involves the insertion of a catheter to deliver chemotherapy directly to the tumor.","indications":["Glioblastoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOak13TVNHZUtBYk1GTG40blBZVHlxT2pfOVVDY2p3aktkYktvOTI1TGdsMzkwaW1nd3o4djl5UWFjOGFVa1ZCcXF4NXRmY2N3ZTdGM2YydHRfRUNtR1l5d1Q0RnBpVUptbkpoa1llWlFtQTMyX0pZN2dydDAwQUs2VWdVTk9oMEhvTFVFaHhqSjdFYVowa1p1eXRWMA?oc=5","date":"2025-12-24","type":"pipeline","source":"BioWorld News","summary":"Hanx Bio sees stock drop 46% in $75M Hong Kong IPO debut - BioWorld News","headline":"Hanx Bio sees stock drop 46% in $75M Hong Kong IPO debut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOT3V0UTc3SUE5NDZKYmcxR292V2pYcVhMWjlfaGRfZlpqYTlQYzhRd3RoNXI3N3doZU5ReEVoZmI4RUlBYkM2VWJwNnFWc2xwajk0eWp4RWJvWnZVS1NrRlJuOHlVX1BxQmZPWXMwWFRKWjBpU240ajlrUzNpcWpwR05RMUtycGNUMHZmOHRMWEtNS1NxLUxmNXJxWnlPREhkbThuS0RSSU15cWM5ZUJUam0zd3ZhOGJVaTB3TDl2WTlBMHFKNzZ1NDFpaXNUYzM2LWgtcUl4VHNNbm8yWVc1SVZTT1ota2ZJb3RZVGphY0hOR2FsZ1R5MWs4NVk3MEVYd1dWMk8xSEIwRUZJ?oc=5","date":"2025-04-24","type":"pipeline","source":"PR Newswire","summary":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight - PR Newswire","headline":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | Del","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-10-02","type":"regulatory","source":"GlobeNewswire","summary":"SERD Market is Predicted to Exhibit Remarkable Growth Owing - GlobeNewswire","headline":"SERD Market is Predicted to Exhibit Remarkable Growth Owing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}